AR033965A1 - Uso de un antagonista de tnfalfa, para tratar o inhibir la lesion celular o la muerte de las celulas - Google Patents

Uso de un antagonista de tnfalfa, para tratar o inhibir la lesion celular o la muerte de las celulas

Info

Publication number
AR033965A1
AR033965A1 ARP010100604A ARP010100604A AR033965A1 AR 033965 A1 AR033965 A1 AR 033965A1 AR P010100604 A ARP010100604 A AR P010100604A AR P010100604 A ARP010100604 A AR P010100604A AR 033965 A1 AR033965 A1 AR 033965A1
Authority
AR
Argentina
Prior art keywords
tnfalfa
antagonist
death
cells
inhibit
Prior art date
Application number
ARP010100604A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR033965A1 publication Critical patent/AR033965A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Uso de antagonista TNFalfa para la elaboración de un medicamento para e tratamiento o inhibición de la lesión celular o la muerte de las células después de un evento isquémico, el tratamiento o inhibición de la lesión por reperfución y la reducción de la mortalidad posterior al infarto de miocardio.
ARP010100604A 2000-02-10 2001-02-09 Uso de un antagonista de tnfalfa, para tratar o inhibir la lesion celular o la muerte de las celulas AR033965A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50186200A 2000-02-10 2000-02-10

Publications (1)

Publication Number Publication Date
AR033965A1 true AR033965A1 (es) 2004-01-21

Family

ID=23995312

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100604A AR033965A1 (es) 2000-02-10 2001-02-09 Uso de un antagonista de tnfalfa, para tratar o inhibir la lesion celular o la muerte de las celulas

Country Status (9)

Country Link
EP (1) EP1261364A1 (es)
JP (1) JP2003522155A (es)
CN (1) CN1406132A (es)
AR (1) AR033965A1 (es)
AU (1) AU2001236764A1 (es)
BR (1) BR0108193A (es)
CA (1) CA2399436A1 (es)
MX (1) MXPA02007683A (es)
WO (1) WO2001058473A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072060A2 (en) 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
WO2013059406A1 (en) 2011-10-18 2013-04-25 Coherus Biosciences, Inc. Etanercept formulations stabilized with metal ions
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
EP2869817A4 (en) 2012-07-09 2016-04-06 Coherus Biosciences Inc STABLE AQUEOUS FORMULATIONS OF ETANERCEPT
BR112015005161A2 (pt) 2012-09-11 2017-07-04 Coherus Biosciences Inc etanercepte corretamente dobrado em alta pureza e excelente rendimento
BR112019007858A2 (pt) 2016-10-21 2019-07-02 Amgen Inc formulações farmacêuticas e métodos para produzir as mesmas

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0939121T4 (da) * 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
AR016551A1 (es) * 1997-07-30 2001-07-25 Smithkline Beecham Corp Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos
NL1007890C2 (nl) * 1997-12-24 1999-07-12 Dutch Trading Dutra B V Samenstel van een railsysteem, ten minste één stuk doek en een aantal bevestigingselementen voor bevestiging van het doek aan het railsysteem.
FR2779724B1 (fr) * 1998-06-10 2001-04-20 Rhone Poulenc Rorer Sa Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent
EP1171148A2 (en) * 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders

Also Published As

Publication number Publication date
JP2003522155A (ja) 2003-07-22
CA2399436A1 (en) 2001-08-16
CN1406132A (zh) 2003-03-26
MXPA02007683A (es) 2002-12-13
BR0108193A (pt) 2003-02-25
AU2001236764A1 (en) 2001-08-20
EP1261364A1 (en) 2002-12-04
WO2001058473A1 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
CU23423B7 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea
BR0113643A (pt) Compostos de guanidinobenzamidas como agonistas de mc4-r e seus usos
AR023966A1 (es) Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP055840A (es) Derivados de 4 -tetrazolil-4fenilpiperidina para el tratamiento del dolor
BRPI0408858A (pt) uso de um inibidor de ibat ou, um sal, solvato, solvato de um tal sal ou uma pró-droga destes, farmaceuticamente aceitáveis, composição farmacêutica, e, método de tratamento e/ou profilaxia de constipação em um animal de sangue quente
AR023078A1 (es) Un articulo para la higiene personal inhibidor de la irritacion de la piel y un metodo para secuestrar irritantes de la piel
BR0115067A (pt) Análogos de gnrh para tratamento de incontinência urinária
BR0307712A (pt) Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal
GT200300294A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
AR033965A1 (es) Uso de un antagonista de tnfalfa, para tratar o inhibir la lesion celular o la muerte de las celulas
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
HUP0200152A2 (hu) KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
AR032422A1 (es) Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
PA8618401A1 (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1.3,5(10)-trien-3,16alfa-diol
AR035600A1 (es) Uso de agonistas selectivos del receptor de dopamina d4 en la fabricacion de medicamentos para tratar la disfuncion sexual
ECSP034604A (es) Inhibicion de la dependendia de celulas tumorales del factor de crecimiento
PE20000701A1 (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
DK1015437T3 (da) Benzoxazin- og benzothiazin-derivater og deres anvendelse i lægemidler
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
CO5271686A1 (es) Nuevo uso de (r)-(-)-2-[5-(4-flurofenil)-3-piridilmetil- aminometil]-cromano y de sus sales aceptables para uso fisiologico
UY26307A1 (es) Las rutas sintéticas eficientes para la preparación de los inhibidores de la proteasa del rinovirus y los intermedios claves
PE20020511A1 (es) Uso de antiprogestinas para la induccion de apoptosis en una celula
DE60143132D1 (de) Zusammensetzungen aus organischen extrakten von geum japonicum thunb var. und ihre verwendung

Legal Events

Date Code Title Description
FA Abandonment or withdrawal